Forte Biosciences announces data from trial in celiac disease for FB102

Written by Emily J. Thompson, Senior Investment Analyst

FBRX-0.97%

Updated: Jun 23 2025

0mins

Clinical Trial Results: Forte Biosciences reported positive results from a Phase 1b trial of FB102 for celiac disease, showing significant improvements in histological and inflammatory endpoints compared to placebo, including a notable reduction in gluten-induced symptoms.
Safety Profile: The study involved 32 subjects with no dropouts and primarily mild treatment-emergent adverse events, indicating a favorable safety profile for FB102 without any severe adverse events reported.

Discover Tomorrow's Bullish Stocks Today

Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.

Sign up now to unlock expert insights and stay one step ahead of the market trends.

FBRX

$29.56+Infinity%1D

Analyst Views on FBRX

Wall Street analysts forecast FBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBRX is 65.00 USD with a low forecast of 65.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Analyst Rating

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 29.850

Low

65.00

Averages

65.00

High

65.00

Current: 29.850

Low

65.00

Averages

65.00

High

65.00

Evercore ISI

Outperform

initiated

$65

2025-11-25

Reason

Evercore ISI

Price Target

$65

AI Analysis

2025-11-25

initiated

Outperform

Reason

Evercore ISI initiated coverage of Forte Biosciences with an Outperform rating and $65 price target. There has been a notable re-rating in development-stage microcap companies, especially those with important proof of concept data in 2025 and 2026, notes the analyst. While arguing that Forte "falls squarely in this bucket," the firm notes shares have been slow to get the same bid until the last two weeks, adding that it thinks the setup is "super attractive into a catalyst-rich 2026."

Guggenheim

NULL -> Buy

initiated

$75

2025-08-18

Reason

Guggenheim

Price Target

$75

2025-08-18

initiated

NULL -> Buy

Reason

Guggenheim initiated coverage of Forte Biosciences with a Buy rating and $75 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FBRX

Unlock Now

About FBRX

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for FBRX?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy FBRX?

Get Started Free

Top News

Forte Biosciences announces data from trial in celiac disease for FB102

Discover Tomorrow's Bullish Stocks Today

Analyst Views on FBRX

About FBRX

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Nasdaq Reports Record Q4 2025 Earnings and Growth Insights

ConnectOne Bancorp Q4 2025 Earnings Call Highlights

GH Research (GHRS) Stock Surges 22.36% Ahead of Key Update

Chardan Capital Reaffirms Buy Rating for Forte Biosciences with $61 Price Target

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch